Sharing benchmarks and strategies to elevate IP practices LONDON, Sept. 24, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today released a new survey-based report that reveals insights and best practices for optimizing intellectual property (IP) operations. In the Excellence in IP Operations report, experts highlight challenges and opportunities facing IP operations departments through the lens of strategy alignment, resource allocation, technolog ...

Core Insights - Clarivate Plc has announced a strategic partnership with Relatable Healthcare to enhance product data management and competitive conversion efficiency for medtech sales, contracting, and pricing teams [1][3]. Group 1: Partnership Overview - The partnership aims to provide a Product Relationship Management (PRM) platform that serves as a single source of truth for product information and competitive data, facilitating cost-efficient revenue growth for medtech manufacturers and distributors [2][5]. - The collaboration combines Clarivate's market intelligence with Relatable's enterprise software, equipping medtech companies with insights and tools to improve contract compliance and win new business [5]. Group 2: Platform Features - The Relatable™ platform offers comprehensive competitive intelligence, product specifications, inventory availability, sales collateral, and custom proprietary data management, enabling clients to make informed strategic pricing decisions [3][4]. - The platform supports streamlined sales contracting processes and enhances contract compliance by providing tools and insights for managing the entire contracting cycle effectively [3][4]. Group 3: Industry Challenges - Medtech companies face challenges in communicating product value and analyzing market trends, particularly in a cost-constrained healthcare environment where providers rigorously evaluate purchasing decisions [4]. - To address these challenges, medtech companies require up-to-date competitive intelligence and advanced software to tailor insights for each contracting and sales opportunity [4].

Core Insights - Clarivate Plc has released the Citation Laureates™ 2024 list, which identifies 22 exceptional scientists and economists whose work is considered of Nobel stature, often predicting future Nobel Prize recipients [1][2][3] Group 1: Contributions and Impact - The 2024 Citation Laureates have made significant advancements in various fields, including clean energy, nanotechnology, 3D protein structures, and the economic impact of corruption [2][3] - The laureates are based in leading academic institutions and corporate organizations, with 11 from the United States, six from the United Kingdom, and others from Switzerland, Germany, Israel, and Japan [3] Group 2: Notable Laureates and Their Work - Key figures include Jonathan C. Cohen and Helen H. Hobbs for their research on lipid metabolism leading to new cardiovascular drugs [5] - John M. Jumper and Demis Hassabis from Google DeepMind are recognized for their contributions to AI and protein structure prediction, with AlphaFold being utilized by over 2 million researchers [4][5] - In economics, Janet Currie is acknowledged for her pioneering analysis of child development, while Partha Dasgupta integrates nature into economic frameworks [7] Group 3: Methodology and Historical Context - Since 2002, Clarivate's Institute for Scientific Information has identified potential Nobel Prize recipients based on citation data from the Web of Science, with only 0.01% of indexed articles cited over 2,000 times [4] - The upcoming Nobel Prize announcements are scheduled for October 7-14, 2024, and will be streamed live [8] Group 4: Company Overview - Clarivate is a global provider of transformative intelligence, offering data, insights, and analytics across various sectors, including academia, government, and life sciences [9]

Transforming library discovery with Academic AI that provides users a new and easy way to find trusted content LONDON, Sept. 18, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today launched Primo™ Research Assistant. Developed in collaboration with partners from the library community, the new generative AI-powered library discovery solution offers a seamless experience for students and researchers. It provides immediate answers to natural language ...

Core Insights - The 15th annual Clarivate Pharmavision India conference will focus on improving patient outcomes and resilience in the healthcare ecosystem, taking place on September 25-26, 2024, in Ahmedabad and Hyderabad [1][2]. Industry Focus - The conference aims to address critical challenges in healthcare affordability and access, emphasizing the need for patient-centric approaches to ensure sustainable growth and competitive advantage [2]. - Industry leaders will discuss the integration of innovative strategies in R&D, generics, biosimilars, and healthcare manufacturing to foster collaboration and drive growth [3]. Key Sessions - Notable sessions include discussions on the balance between generics and innovation in Indian Pharma, the role of AI and big data in healthcare, and the integration of cell and gene therapy into clinical practice [3]. - Specific presentations will cover topics such as affordability in the global scenario and creating value for patients and stakeholders [3]. Organizational Role - Clarivate positions itself as a leader in fostering collaboration across life sciences and healthcare industries, aiming to enhance patient outcomes through impactful forums like Pharmavision India [3].

LONDON, Sept. 9, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today launched its first Pulse of the LibraryTM report. The report reveals that libraries are in the early days of Artificial Intelligence (AI) implementation. Librarians are considering applications of AI that support the library mission, particularly in enhancing content discovery and increasing efficiency for their teams. However, there are notable concerns, including a lack of AI ex ...

Developed in partnership with the research community to implement high-quality AI tools responsibly LONDON, Sept. 4, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today released the Web of Science™ Research Assistant. The new generative AIpowered tool helps researchers find key papers faster, handle complex research tasks and visualize connections. The chat interface combined with the Web of Science knowledge graph allows researchers to get more ou ...

LONDON, Aug. 20, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, has appointed Melanie Margolin to the expanded role of Chief Administrative and Legal Officer. She joined the company as Executive Vice President and Chief Legal Officer in September 2023. Ms. Margolin successfully leverages her experience as a seasoned executive to advance key strategic programs at Clarivate. She has a proven track record of establishing strong controls for complex or ...

Investment Action - Clarivate Plc (NYSE: CLVT) is recommended as a buy due to expected organic growth recovery as the macro environment improves, with no structural weaknesses identified in the business [2] - The organic growth recovery story remains intact, with improvements noted in the two largest segments [2] Earnings Review - In Q2 2024, CLVT reported a revenue decline of 2.8% on a reported basis and 0.6% on an organic basis, with transactional revenue down 4.1% and subscription revenue up 0.7% year-over-year [3] - EBITDA margin contracted by 40bps to 42.2%, but EPS exceeded consensus expectations at $0.20 compared to $0.18 [3] - Organic growth improved from -1.7% in Q1 2024 to -0.6% in Q2 2024, driven by the Academia & Government (A&G) and Intellectual Property (IP) segments [3] Segment Performance - A&G segment organic growth accelerated from 0.6% in Q1 2024 to 1.3% in Q2 2024, with subscription revenue growing over 3% and renewal rates exceeding 96% [3] - IP segment organic growth improved from -4.5% in Q1 2024 to -1.8% in Q2 2024, indicating stabilizing trends in trademark search volumes [3] - Life Sciences & Healthcare (LS&H) segment saw a decline in organic growth from 2.8% to 3.9%, attributed to a weak macro environment affecting large pharma budgets [5] Market Outlook - The long-term trend indicates that R&D expenditure typically increases over time, suggesting a potential recovery following the current macro downturn [5] - Expectations for a strong recovery in the LS&H segment by FY25 as pharma companies resume R&D initiatives [5] Valuation - Current valuation at 6.5x forward PE is considered cheap, with potential upside if growth accelerates to 3% by FY26 and margins improve to 22% [7] - Historical margins ranged between 23-25% from FY20 to FY23, with a target of 22% by FY26 [9] Key Takeaways - A&G segment is expected to return to historical low single-digit growth rates as the macro environment improves [8] - IP segment is likely to continue its organic growth improvement as CLVT gains market share [8] - Recovery timing for the LS&H segment is contingent on macroeconomic recovery, anticipated by FY25 [8]

LONDON, Aug. 7, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, announced today that Jonathan Collins, Executive Vice President and Chief Financial Officer, will present at the Oppenheimer 27th Annual Technology, Internet & Communications Virtual Conference, on Monday, August 12, 2024 at 2:55 pm Eastern Time. The live webcast can be accessed at https://wsw.com/webcast/oppenheimer37/clvt/2805750 and will be available for replay. A replay of each webc ...